NCT05722977

Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients

Surufatinib Combined With Envafolimab Followed by Surufatinib as Second or More - Line Therapy for Advanced Soft Tissue Sarcoma in a Single-arm, Phase II Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

In this study, we investigated the efficacy and safty of surufatinib combined with envafolimab followed by surufatinib as second or more - line therapy in advanced soft tissue sarcoma patients. Patients who have failed at least the first-line therapy and have progressive disease or cannot tolerate within 6 months before enrollment will be treated with surufatinib combined with envafolimab.

Conditions

• Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients

Interventions

Type	Name	Description
DRUG	Surufatinib + envafolimab	Surufatinib: oral, fix dose 250mg, once a day; Envafolimab: subcutaneous injection, fix dose 300mg, once every three weeks

Timeline

• Start date: 2023-02-02
• Primary completion: 2026-02-02
• Completion: 2027-02-02
• First posted: 2023-02-10
• Last updated: 2023-02-10